Vaccinogen, Inc.
Biotechnology company developing personalized autologous immunotherapies derived from a patient’s resected tumor to prevent cancer recurrence. Clinical development has focused on an autologous tumor-cell vaccine for advanced Stage 2 colon cancer and on downstream discovery of human monoclonal antibodies (HuMabs) from treated patients for diagnostic and antibody-based therapeutic applications. The company has engaged regulatory pathways (FDA Special Protocol Assessment and Fast Track) and formed manufacturing and clinical consortiums to support late-stage trials and scale-up.
Industries
Nr. of Employees
small (1-50)
Patents
Products
OncoVAX (autologous tumor-derived vaccine)
Patient-specific vaccine manufactured from a resected tumor, administered in multiple doses with adjuvant priming to reduce postoperative recurrence of advanced Stage 2 colon cancer.
OncoVAX (autologous tumor-derived vaccine)
Patient-specific vaccine manufactured from a resected tumor, administered in multiple doses with adjuvant priming to reduce postoperative recurrence of advanced Stage 2 colon cancer.
Services
Coordination with CRO partners to manage and perform late-stage randomized trials using agreed protocols and regulatory approvals.
Engagement of contract manufacturing organizations to produce autologous vaccine doses at scale following validated sterile processes and bioequivalency.
Isolation and development of human monoclonal antibodies from treated patients for downstream diagnostic and therapeutic development.
Coordination with CRO partners to manage and perform late-stage randomized trials using agreed protocols and regulatory approvals.
Engagement of contract manufacturing organizations to produce autologous vaccine doses at scale following validated sterile processes and bioequivalency.
Isolation and development of human monoclonal antibodies from treated patients for downstream diagnostic and therapeutic development.
Expertise Areas
- Personalized immunotherapy
- Autologous vaccine manufacturing
- Clinical trial design and execution
- Regulatory strategy and FDA interactions
Key Technologies
- Autologous cell therapy manufacturing
- Adjuvant-based immune priming (BCG)
- Human monoclonal antibody generation from patient B cells
- Bispecific T-cell engager engineering
News & Updates
The company received FDA Special Protocol Assessment and Fast Track designation for its Phase IIIB trial protocol; the FDA approved the Phase IIIB protocol in September 2015 with DFS as the primary endpoint and an interim analysis schedule.
A bioequivalency study for a sterile version of the autologous product was completed in October 2003 following development of a sterilization approach.
Historical Phase III and earlier trials reported improved disease-free survival and durable outcomes in subsets of Stage 2 colon cancer patients; trials include ECOG 5283 and the 8701 study.
The company received FDA Special Protocol Assessment and Fast Track designation for its Phase IIIB trial protocol; the FDA approved the Phase IIIB protocol in September 2015 with DFS as the primary endpoint and an interim analysis schedule.
A bioequivalency study for a sterile version of the autologous product was completed in October 2003 following development of a sterilization approach.
Historical Phase III and earlier trials reported improved disease-free survival and durable outcomes in subsets of Stage 2 colon cancer patients; trials include ECOG 5283 and the 8701 study.